CNBC reports that newly released data published Monday in the medical journal The Lancet revealed that the potential coronavirus vaccine developed by Oxford University with pharmaceutical giant AstraZeneca has produced a strong immune response in a large, early-stage human trial.

The researchers said the vaccine produced both antibodies and killer T-cells to combat the infection. Neutralizing antibodies, which scientists believe is important to gain protection against the virus, were detected in participants after 28 days.